Track Scinai Immunotherapeutics Ltd. American Depositary Shares — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Scinai Immunotherapeutics Ltd. American Depositary Shares SCNI Open Scinai Immunotherapeutics Ltd. American Depositary Shares in new tab

0.4849 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateJuly 7, 2026

DCF Valuation

Tweak assumptions to recompute fair value for Scinai Immunotherapeutics Ltd. American Depositary Shares (SCNI)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Scinai Immunotherapeutics Ltd. American Depositary Shares Logo Scinai Immunotherapeutics Ltd. American Depositary Shares Analysis (SCNI)

Israel Health Care Official Website Stock

Is Scinai Immunotherapeutics Ltd. American Depositary Shares a good investment? Scinai Immunotherapeutics Ltd. American Depositary Shares (SCNI) is currently trading at 0.4849 USD.

Earnings Schedule: Scinai Immunotherapeutics Ltd. American Depositary Shares is expected to release its next earnings report on July 7, 2026.

Investor FAQ

Does Scinai Immunotherapeutics Ltd. American Depositary Shares pay a dividend?

No, it does not currently pay a dividend.

What asset class is Scinai Immunotherapeutics Ltd. American Depositary Shares?

Scinai Immunotherapeutics Ltd. American Depositary Shares is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be July 7, 2026.

Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Exchange Ticker
NMS (United States) SCNI
FRA (Germany) 2F5.F

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
May 21, 2024 0.100000
Nov. 25, 2022 0.100000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion